Triangle Securities Wealth Management raised its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 39,249 shares of the biopharmaceutical company’s stock after purchasing an additional 190 shares during the period. Bristol-Myers Squibb accounts for about 1.4% of Triangle Securities Wealth Management’s portfolio, making the stock its 25th largest position. Triangle Securities Wealth Management’s holdings in Bristol-Myers Squibb were worth $2,187,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp grew its position in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after buying an additional 1,223,457 shares during the last quarter. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after buying an additional 178,436 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares during the last quarter. Legal & General Group Plc grew its position in shares of Bristol-Myers Squibb by 4.3% in the 1st quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after buying an additional 335,795 shares during the last quarter. Finally, Swiss National Bank grew its position in shares of Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares during the last quarter. 68.80% of the stock is currently owned by institutional investors and hedge funds.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Triangle Securities Wealth Management Boosts Holdings in Bristol-Myers Squibb Company (BMY)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/triangle-securities-wealth-management-boosts-holdings-in-bristol-myers-squibb-company-bmy.html.

Shares of Bristol-Myers Squibb Company (BMY) traded up 0.80% during mid-day trading on Thursday, reaching $62.98. 1,939,771 shares of the company’s stock traded hands. The firm’s 50-day moving average is $57.94 and its 200 day moving average is $55.81. The firm has a market cap of $103.28 billion, a price-to-earnings ratio of 23.00 and a beta of 1.18. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 earnings per share. Analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.50%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

A number of brokerages have recently issued reports on BMY. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price objective on the stock. in a research report on Thursday, September 7th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday, September 8th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $66.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday. Finally, Hilliard Lyons downgraded shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective on the stock. in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $62.31.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.